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2009; Rau et al., 2009). Furthermore, 
MrgprB4 is expressed in sensory neu-
rons that may detect gentle touch (Liu 
et al., 2007). Therefore, Mrgprs play 
important but apparently distinct roles 
in somatosensation. Still, the endog-
enous modulators of Mrgprs under 
physiological and pathophysiological 
conditions are largely unknown. Eluci-
dating relevant endogenous or exog-
enous ligands for this class of receptors 
will be an important future direction. 
The molecular pathways downstream of 
Mrgprs also remain to be unraveled.
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Circulating tumor cells are responsible for seeding metastatic growth at distant sites. Kim et al. 
(2009) now discover that circulating tumor cells can reinfiltrate tumors at their primary organs and 
promote tumor progression.Cancer progression is traditionally viewed 
as a sequential tumorigenic process. 
Tumor cells at the primary sites gradually 
acquire the capacity to invade and intra-
vasate into the systemic circulation. These 
circulating tumor cells serve as conduits 
for the spread to distant organs. However, 
successful colonization at distant organs 
is dependent on acquisition of the ability 
of circulating tumor cells to leave circu-
lation (by extravasation) and to adapt to 
the new microenvironment (Chambers et 
al., 2002). Emerging evidence indicates 
that disseminated tumor cells are present 
in the circulation in large numbers even 
at early stages of cancer, long before 
metastatic growth at distant sites can be 
detected (Husemann et al., 2008). One 
recent study has demonstrated that even 
apparently untransformed mammary epi-
thelial cells can take residence at distant 
organs, such as the lung, for an extended 1226 Cell 139, December 24, 2009 ©2009 Eperiod of time, and that later induction of 
transformation is sufficient to induce met-
astatic growth (Podsypanina et al., 2008). 
In this issue, Massagué and colleagues 
(Kim et al., 2009) add another twist to 
our understanding of tumor progression, 
showing that the flow of circulating tumor 
cells is not a one-way street—circulating 
cancer cells can reinfiltrate tumors at their 
organs of origin to promote the growth of 
the primary tumors (Figure 1).
The low rate of successful metastatic 
growth is at least in part due to rate-
limiting steps involving acquisition of the 
ability to extravasate and to adapt to new 
microenvironments. Massagué and col-
leagues reasoned that circulating tumor 
cells should require little adaptation to 
survive and grow at tumors from their 
primary organs. To test this hypothesis, 
the authors set up a clever tumor-seeding 
assay based on tumor xenograft mod-lsevier Inc.els in mice. By implanting differentially 
labeled tumor xenografts at distinct ana-
tomical locations within the same mouse, 
they asked if tumor cells disseminated 
from one xenograft could home to the 
second xenograft over time. The authors 
found that metastatic tumor cells injected 
into the mammary fat pad, under the skin, 
or intravenously, or tumor cells shed from 
metastatic lesions, are readily detectable 
in a contralateral recipient xenograft after 
2 months. This tumor self-seeding phe-
nomenon is observed with tumor cells 
from breast, colon, and skin, suggesting 
that this is a general phenomenon in epi-
thelial tumors.
Massagué and colleagues further show 
that recipient tumors are preferentially 
seeded by highly metastatic derivatives 
from the tumor cell lines tested. In addi-
tion, these “seeder” cells colonize only to 
pre-existing tumors, not to the intact or 
mock-inoculated mammary glands. Gene 
expression analysis of these metastatic 
seeder populations identified a profile 
characteristic of mammary metastatic 
cells in brain, bone, and lung, suggest-
ing that the ability to self-seed is common 
for metastatic cells with diverse tropisms. 
Further studies with breast cancer and 
melanoma models demonstrate that the 
process involves chemoattraction medi-
ated by tumor-derived cytokines interleu-
kins 6 and 8 (IL-6 and IL-8) and infiltration 
of seeder cells through actions of matrix 
metalloproteinase 1 (MMP1) and the actin 
bundling protein Fascin-1.
These experiments highlight the dis-
tinct roles of donor and recipient tumor 
populations in orchestrating tumor self-
seeding. The importance of IL-6 and 
IL-8 as chemoattractants that recruit 
seeder tumor cells raises several inter-
esting questions. IL-6 plays diverse roles 
in tumor growth (Schafer and Brugge, 
2007) and cell transformation (Iliopoulos 
et al., 2009). Inflammatory cytokines are 
also implicated in the maintenance of 
vasculature integrity (Dittmar et al., 2008) 
and may play an additional role in facili-
tating extravasation of the seeder cells. 
Moreover, many studies have shown that 
various epithelial tumors or their stromal 
components express IL-6 and IL-8. 
The differential affinity of the circulat-
ing breast cancer and melanoma tumor 
cells in the study to be attracted to IL-6 
and IL-8 suggests that the spectrum of 
cytokine receptor expression influences 
target site selection. The central roles of 
MMP1 and Fascin-1 in tumor infiltration 
during self-seeding are consistent with 
previous studies showing that the expres-
sion of these two proteins is associated 
with tumor relapse and metastasis (Bos 
et al., 2009), highlighting the similarities 
between infiltration in self-seeding and 
metastasis at distant sites.
The intriguing observation of tumor self-
seeding led the authors to investigate the 
role of this process in tumor progression 
at the organismal level. They compared 
the growth rates of control tumors and 
primary tumors seeded by the circulating 
cells after accounting for the addition of 
the seeder populations. They found that 
the seeded tumors have an accelerated 
growth rate, supporting a role of tumor 
self-seeding in promoting growth of the 
primary tumor. The authors also observe figure 1. Tumor self-seeding by circulating Tumor cells
Circulating tumor cells reinfiltrate tumors at primary sites in a newly identified phenomenon called 
“tumor self-seeding.” Metastatic tumor cells in the circulation (brown cells) can seed not only distant 
metastasis but also existing tumors within the primary organs (gray cells). These existing tumors se-
crete chemoattractants, such as interleukins 6 and 8, to recruit circulating tumor cells. These tumor 
cells infiltrate the primary tumor and promote growth, angiogenesis, and recruitment of stromal com-
ponents (yellow cells).enhanced angiogenesis and stromal 
recruitment, including leukocytes, mac-
rophages, neutrophils, and myeloid cells. 
In at least one model using a breast can-
cer cell line, this recruitment is mediated 
by the cytokine CXCL1 produced by the 
seeder cells. Together, these observa-
tions support the notion that tumor self-
seeding could promote primary tumor 
growth, enhance angiogenesis, and 
recruit stromal components.
Tumor microenvironments support 
tumor growth and promote tumor pro-
gression. Several studies demonstrate 
that components in the tumor stroma, 
such as mesenchymal stem cells, tumor-
associated fibroblasts, and myofibro-
blasts, nourish various steps of tumor 
progression (Husemann et al., 2008; 
Karnoub et al., 2007). Another elegant 
study has shown that the presence of 
a distinct tumor could stimulate growth 
of separate tumors at anatomically dis-
tant sites by promoting incorporation of 
bone marrow cells to the distant tumors 
(McAllister et al., 2008). The current study 
demonstrates yet another phenomenon 
by which tumor cells cooperate to pro-
mote tumor progression and highlights Cell 139, Deadditional processes, beyond genetic 
and epigenetic alterations, that contrib-
ute to cellular heterogeneity within pri-
mary tumors.
The intriguing phenomenon of tumor 
self-seeding provides new insights into 
the dynamics of tumor progression. It 
also provokes many interesting ques-
tions; most importantly, does tumor 
self-seeding play a role in human cancer 
progression and how does this phenom-
enon influence pathologic outcome? 
Although the data in this study provide 
evidence that tumor self-seeding pro-
motes primary tumor growth, how this 
process ultimately influences cancer 
progression and distant metastases 
remains to be established. It is tempt-
ing to speculate that self-seeding might 
occur not only at the primary tumor site, 
but also at distinct metastatic sites. Each 
site could serve as a nesting ground to 
generate tumor variants that repopu-
late other metastatic sites as well as the 
primary tumor, thus accelerating tumor 
progression. Elucidating the interplay 
between tumor self-seeding and other 
tumorigenic processes will be crucial to 
our understanding of tumor evolution.cember 24, 2009 ©2009 Elsevier Inc. 1227
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